ChemBriefGoldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO
Biopharmaceutical firm Attovia Therapeutics targets a $731.5 million valuation in an upsized US IPO to raise $289 million for developing biologic therapies for immune-mediated diseases. Goldman Sachs
reuters · 2026-08-04 04:53